SNTI News and Press, Senti Biosciences Inc. From 12/11/22

– ASH poster presentation summarizes preclinical data from SENTI-202, an off-the-shelf CAR-NK cell therapy candidate engineered with a logic-gated gene circuit and multi-armed with crIL-15, that is advancing toward clinical development for hematologic malignancies – ȁ...

– Review of new preclinical data and clinical development plan for SENTI-202 in hematologic malignancies; also featuring KOL discussion of treatment landscape and unmet need in AML – – Live and webcast event on Sunday, December 11, 11:30 am - 12:30 pm CST &#...

Senti Biosciences press release ( NASDAQ: SNTI ): Q3 GAAP EPS of -$0.38 beats by $0.12 . Revenue of $1.77M (+60.9% Y/Y) beats by $0.84M . As of September 30, 2022, Senti Bio held cash and cash equivalents of $114.9 million, which the Company believes is suffici...

- SENTI-202 on track for IND filing in 2023; clinical plans for SENTI-202 expand beyond AML to CD33 and/or FLT3 expressing hematologic malignancies including MDS - - Selected development candidate for program to treat GPC3-expressing solid tumors including HCC, SENTI-301A; e...

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary gene circuit technology platform, today announced a poster pres...

SOUTH SAN FRANCISCO, Calif., Oct. 28, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary gene circuit platform, today announced that on October 27, 2022...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips While the below market ideas may very well represent the best penny stocks under $3 to buy now, you must realize the dirty little secret. Usually, when publicly traded securities fall this low, it’s not for good reas...

Palm Beach, FL – October 5, 2022 – FinancialNewsMedia.com News Commentary – Advanced pancreatic ductal adenocarcinoma (PDAC) remains a significant cause of mortality accounting for up to 4% of all cancer-related deaths worldwide. Of concern, despite treatmen...

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary gene circuit platform, today announced two poster presentations...

3 Penny Stocks to Watch as the Stock Market Remains Volatile Investing in penny stocks can be a great way to build your wealth over time. But it’s not without its risks. Before you decide to buy penny stocks, it’s important to understand the potential rewards and risks inv...